What is Empire Genomics?
Empire Genomics operates at the intersection of clinical diagnostics and molecular research, providing a comprehensive suite of Fluorescence In Situ Hybridization (FISH) probes. By leveraging an extensive BAC library derived from the Human Genome Project, the company delivers high-precision tools, including ASR, Break Apart, and disease-specific probes. Their market position is defined by a commitment to workflow efficiency, offering both manual and automated solutions alongside custom probe design services. This specialized focus on life sciences tools allows the company to serve as a critical partner for clinical laboratories, facilitating rapid turnaround times and reliable diagnostic outcomes in complex genetic testing environments.
How much funding has Empire Genomics raised?
Empire Genomics has raised a total of $18.4M across 5 funding rounds:
Debt
$1.3M
Unspecified
$15M
Debt
$300K
Private Equity
$1.8M
Debt
$150K
Debt (2014): $1.3M with participation from Rand Capital Corporation
Unspecified (2015): $15M, investors not publicly disclosed
Debt (2016): $300K supported by Rand Capital Corporation
Private Equity (2016): $1.8M featuring Rand Capital and BroadOak Capital Partners, LLC
Debt (2020): $150K backed by PPP
Key Investors in Empire Genomics
Rand Capital Corporation
Rand Capital Corporation is an externally managed business development company that provides debt and related equity capital to privately held lower middle market businesses across a range of industries.
BroadOak Capital Partners, LLC
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies.
PPP
Public-Private Partnership
What's next for Empire Genomics?
Looking ahead, the strategic deployment of the $150K will likely focus on accelerating the development of next-generation diagnostic reagents and expanding the company's automated probe design capabilities. As the demand for personalized medicine and targeted therapy selection grows, Empire Genomics is poised to leverage its existing infrastructure to capture additional market share in the biopharma services sector. The company's roadmap suggests a continued emphasis on operational excellence and the integration of advanced genomic technologies, ensuring that its diagnostic offerings remain at the forefront of clinical utility. By fostering deeper partnerships with research institutions and diagnostic providers, Empire Genomics aims to solidify its status as a cornerstone of the modern molecular diagnostics ecosystem.
See full Empire Genomics company page
